Boston Scientific (BSX) is gaining from new product launches and accretive acquisitions. Yet, unfavorable currency movement and macroeconomic concerns are major dampeners. The stock carries a Zacks Rank #3 (Hold).Factors Driving BSX SharesBoston Scientific’s Endoscopy business within MedSurg is witnessing strong growth in endoluminal surgery and single-use imaging franchises, along with sustained growth of the AXIOS platform, where the company is reinvesting to drive expanded indications. It recently receiv ...

POLAND - 2024/11/21: In this photo illustration, the Boston Scientific company logo is seen ... [+] displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)SOPA Images/LightRocket via Getty ImagesBoston Scientific stock (NYSE: BSX) has gained 3% in the five days since its Q4 earnings report last week. Although the company exceeded expectations with both its results and guidance, the modest stock increase may be due to the significant price appreciation ah ...

Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, February 10th:Boston Scientific Corporation (BSX) : This medical devices company has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 5.2% over the last 60 days.Boston Scientific’s shares gained 19.3% over the last three months compared with the S&P 500’s advance of 0.4%. The company possesses a Momentum Score  of A.Enova International, Inc. (ENVA) : Thi ...

Here are five stocks added to the Zacks Rank #1 (Strong Buy) List today:Peoples Financial Services Corp. (PFIS) : This bank holding company for Peoples Security Bank and Trust Company has seen the Zacks Consensus Estimate for its current year earnings increasing 10.2% over the last 60 days.Boston Scientific Corporation (BSX) : This medical devices company has seen the Zacks Consensus Estimate for its current year earnings increasing 5.2% over the last 60 days.Enova International, Inc. (ENVA) : This technolo ...

Momentum investing revolves around the idea of following a stock's recent trend in either direction. In the 'long' context, investors will be essentially be "buying high, but hoping to sell even higher." With this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving that way. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.While many investors like to look for moment ...

Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Is Boston Scientific (BSX) one of those stocks right now? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.Boston Scientific is one of 1012 individual stocks in the Medical sector. Collectively, these companies sit at #3 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is ...

Financial Data and Key Metrics Changes - In Q4 2024, operational sales grew 23% and organic sales grew 20%, exceeding the guidance range of 14% to 16% [10] - Full year 2024 operational sales grew 18.5% while organic sales grew 16%, surpassing the guidance of approximately 15% [10] - Q4 adjusted EPS was $0.70, a 26% increase, exceeding the guidance range of $0.64 to $0.66 [11] - Full year adjusted EPS was $2.51, a 22% increase, exceeding the guidance range of $2.40 to $2.47 [11] - Adjusted operating margin for full year 2024 was 27%, an increase of 70 basis points [12] Business Line Data and Key Metrics Changes - Urology grew 8% in Q4 and 9% for the full year, with operational growth of 20% in Q4 [17] - Endoscopy sales grew 8% operationally and 7% organically in Q4, with full year growth of 9% operationally [20] - Cardiology sales grew 32% in Q4 and 25% for the full year, with interventional cardiology therapies growing 10% in Q4 [23] - Electrophysiology sales grew 172% in Q4 and 139% for the full year, driven by FerraPulse [29] Market Data and Key Metrics Changes - U.S. operational growth was 31% in Q4 and 21% for the full year [14] - Asia Pacific grew 12% operationally in Q4 and 16% for the full year, with strong performance in Japan and China [15] - Middle East, Europe, and Africa grew 12% in Q4 and 14% for the full year [14] Company Strategy and Development Direction - The company aims to continue outpacing market growth in 2025, with expectations of organic growth of 14% to 16% [12] - Focus on innovation and execution across global business units, with significant investments in product development [10] - Strategic acquisitions, such as Bolt Medical and Intera Oncology, are expected to enhance the product portfolio [12][24] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in maintaining strong growth momentum despite potential competition in the PFA market [75] - Anticipated challenges in China due to VBP pricing pressures, but still expect mid-teens growth [17] - Management remains focused on driving differentiated results and enhancing the company culture [36] Other Important Information - Free cash flow for Q4 was $1.181 billion, with full year free cash flow of $2.648 billion, achieving 71% conversion [43] - The company has a cash reserve of $414 million and a gross debt leverage ratio of 2.2 times [44] - Guidance for 2025 includes reported revenue growth of 12.5% to 14.5% and organic growth of 10% to 12% [45] Q&A Session Summary Question: Thoughts on PFA and Watchmen growth - Management noted excellent momentum in both FerraPulse and Watchmen, with a slight uptick in Watchmen growth due to reimbursement changes [60] Question: Long-term growth expectations - Management indicated a goal to outgrow market growth rates and maintain double-digit EPS growth despite potential tax rate increases [68] Question: Risks and upside in guidance - Management acknowledged potential competition in the PFA market but emphasized strong momentum across various regions and product lines [75] Question: Margin management and cash flow - Management discussed strategies for operating margin expansion and maintaining a focus on high-quality M&A as a primary use of cash [85] Question: Update on TAVR franchise - Management stated that discussions regarding the U.S. TAVR franchise are ongoing, with strong performance in Europe despite some impacts from U.S. trials [123] Question: Mapping strategy and market share - Management confirmed an open platform strategy for mapping, with a focus on enhancing the OPAL platform while supporting competitive systems [126]

Boston Scientific Corporation (BSX) posted fourth-quarter 2024 adjusted earnings per share (EPS) of 70 cents, up 27.3% from the year-ago figure. The figure beat the Zacks Consensus Estimate by 7.7% and also exceeded the company’s adjusted earnings per share guidance range of 64-66 cents per share.Find the latest EPS estimates and surprises on Zacks Earnings Calendar.The quarter’s adjustments included certain amortization expenses, acquisition/divestitures-related net charges, and restructuring and restructu ...

Boston Scientific (BSX) came out with quarterly earnings of $0.70 per share, beating the Zacks Consensus Estimate of $0.65 per share. This compares to earnings of $0.55 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 7.69%. A quarter ago, it was expected that this medical device manufacturer would post earnings of $0.58 per share when it actually produced earnings of $0.63, delivering a surprise of 8.62%.Over the last four qua ...

FOR IMMEDIATE RELEASE Boston Scientific announces results for fourth quarter and full year 2024 For the full year 2024, the company generated net sales of $16.747 billion, growing 17.6 percent on a reported basis, 18.5 percent on an operational basis and 16.4 percent on an organic basis. The company reported GAAP net income attributable to Boston Scientific common stockholders of $1.853 billion or $1.25 per share, compared to $1.570 billion or $1.07 per share a year ago, and delivered full year adjusted EPS ...